Prescribing overview
Simparica Trio combines flea/tick, heartworm-prevention and selected intestinal-worm coverage. It differs from single-ingredient Simparica and requires the correct age and weight presentation.
Simparica Trio combines flea/tick, heartworm-prevention and selected intestinal-worm coverage. It differs from single-ingredient Simparica and requires the correct age and weight presentation.
Key prescribing checks
- Confirm the indication, route, current weight, disease status and concurrent treatments before prescribing.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Dogs
FDA-approved canine productHeartworm prevention; labeled flea/tick and roundworm/hookworm control; specified vector-mediated infection prevention
US dogs at least eight weeks old and 2.8 lb; exact parasite species and life stages are limited to current labeling.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Sarolaner targets arthropod chloride channels; moxidectin targets susceptible nematodes; pyrantel causes susceptible intestinal nematode paralysis.
Absorption, distribution, metabolism and elimination
Sarolaner and moxidectin are systemically absorbed and largely eliminated through bile; formulation-specific studies do not establish another product’s interchangeability.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Simparica Trio
US dogs at least eight weeks old and 2.8 lb; exact parasite species and life stages are limited to current labeling.
Contraindications · when not to use
- The reviewed label reports no known contraindications; precautions and eligibility restrictions still apply.
Precautions & monitoring
- Caution with neurologic disease. Test for existing heartworms; this is not adult-heartworm treatment. Reproductive safety was not evaluated.
Selected product information; this is not a complete interaction or patient-specific prescribing assessment.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Vomiting, diarrhea and lethargy were reported. Isoxazoline-associated neurologic effects include tremor, ataxia and seizures, including without prior seizures.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.
No numeric regimen is supplied in this entry. The veterinarian must consult the exact current product label; this entry does not enable a dosing calculator.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This monograph summarizes selected interactions. The comparison tool applies a curated set of rules and is not comprehensive. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Compare with other medications and check species →
Simparica Trio
US dogs at least eight weeks old and 2.8 lb; exact parasite species and life stages are limited to current labeling.
- No universal compatibility conclusion follows from the label. Check overlapping antiparasitic ingredients and the complete treatment plan.
Monitoring
Verify heartworm testing, weight-band selection, full ingestion, parasite-control response and neurologic changes.
Client counseling
Record administration dates and review missed doses with the veterinarian. Preventing flea-vectored tapeworm infection does not treat established tapeworms.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Follow the current package storage instructions.
Brands, formulations & ingredient identity
Active ingredients
Sarolaner · Moxidectin · pyrantel pamoate
Other searchable names: Simparica Trio
This reference is limited to the named product and presentation; matching ingredients do not establish interchangeability.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Simparica Trio
- Formulation
- Canine chewable tablets
- Label / product scope
- Dogs
US dogs at least eight weeks old and 2.8 lb; exact parasite species and life stages are limited to current labeling.
Product label / source ↗References & review status
Clinical reference updated October 27, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
